Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan最新文献_第5页

[Radiotheranostics Based on Chemical Control of Radioactivity Pharmacokinetics]. [基于放射性药代动力学化学控制的放射治疗]。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00168-3

Masahiro Ono

{"title":"[Radiotheranostics Based on Chemical Control of Radioactivity Pharmacokinetics].","authors":"Masahiro Ono","doi":"10.1248/yakushi.23-00168-3","DOIUrl":"10.1248/yakushi.23-00168-3","url":null,"abstract":"Recently, radiotheranostics, which systematically combines diagnosis by nuclear medicine imaging and treatment by internal radiotherapy, constitutes a new modality in cancer treatment, with some clinical reports showing marked effects on cancer. We have been developing multifunctional chelates containing a target recognition unit, a radiation release unit, and a radioactivity pharmacokinetics control unit in the same molecule to develop efficient agents for cancer radiotheranostics based on chemical control of radioactivity pharmacokinetics. Using these compounds, we have achieved improved cancer accumulation and reduced renal accumulation in tumor-bearing mice, and have developed novel hybrid radiotheranostic agents that can be applied to simultaneously perform target-specific molecular imaging using γ-ray emitting radionuclides and internal radiotherapy using α-particle-emitting radionuclides. For example, 111In/225Ac-labeled PSMA-DA1, which targets prostate-specific membrane antigen (PSMA) for radiotheranostics, achieved clear in vivo imaging of PSMA in tumor-bearing mice and showed marked tumor growth inhibition. In addition to PSMA, this platform for radiotheranostics has also shown efficacy against various cancer target molecules, including carbonic anhydrase IX (CA-IX), which is highly expressed in hypoxic regions of cancer, and glucagon-like peptide-1 receptor (GLP-1R), which is highly expressed in insulinomas. This review presents these recent results of our studies on radiotheranostics for cancer.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"144 3","pages":"291-297"},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Preparation of Nanoplastic Particles as Potential Standards for the Study of Nanoplastics]. [制备纳米塑料粒子作为研究纳米塑料的潜在标准]。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00152-1

Kosuke Tanaka, Yusuke Takahashi, Hidetoshi Kuramochi, Masahiro Osako, Go Suzuki

{"title":"[Preparation of Nanoplastic Particles as Potential Standards for the Study of Nanoplastics].","authors":"Kosuke Tanaka, Yusuke Takahashi, Hidetoshi Kuramochi, Masahiro Osako, Go Suzuki","doi":"10.1248/yakushi.23-00152-1","DOIUrl":"10.1248/yakushi.23-00152-1","url":null,"abstract":"Nanoplastics (NPs) are plastic fragments that are small enough to be absorbed by organisms through ingestion or inhalation. Recent studies indicate that nanoplastics can be ubiquitous in the environment, and there are growing concerns regarding the impacts of nanoplastics on the health of humans and other organisms. However, quantitative information on nanoplastics in the environment is still very limited, and most previous toxicity studies have used only polystyrene (PS) particles because of a lack of appropriate model particles of other plastics. We developed a nanoprecipitation-based method for the preparation of nanoplastic particles of five major polymers: low-density polyethylene (LDPE), high-density polyethylene (HDPE), polypropylene (PP), polyvinyl chloride (PVC), and polystyrene. A major advantage of our method is that the nanoplastic particles are prepared without using reagents that can remain in the particles as impurities. Analysis of the prepared particles' molecular weight (Mw) distributions, crystallinities, and thermal properties revealed that their compositions and constitutions were within the general ranges for commercial products. The mechanisms underlying the formation of low-density polyethylene particles via our method were investigated by means of a simple population balance model, and particle diameter was found to be linearly correlated with the suspension density of the nanoplastic dispersion up to 0.4 mg·mL-1. Future studies should focus on improving our method to allow for precise, scale-independent production of nanoplastic particles. Methods for the preparation of labeled particles are also needed so that such particles can be used in nanoplastic risk assessments.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"144 2","pages":"165-170"},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139724208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Nationwide Survey on Medication Follow-up Care by Community Pharmacists: From The Japanese Nationwide Pharmacy Collaboration Survey in 2023. 关于社区药剂师用药随访护理的全国性调查：2023 年日本全国药房协作调查》。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 DOI: 10.1248/yakushi.24-00016

Shu Sekiya, Rei Tanaka, Hisashi Iijima, Yoshio Nakano, Satoru Miyazaki, Atsushi Toyomi, Hajime Hashiba, Masanori Nagatsu, Yoshiaki Shikamura

{"title":"A Nationwide Survey on Medication Follow-up Care by Community Pharmacists: From The Japanese Nationwide Pharmacy Collaboration Survey in 2023.","authors":"Shu Sekiya, Rei Tanaka, Hisashi Iijima, Yoshio Nakano, Satoru Miyazaki, Atsushi Toyomi, Hajime Hashiba, Masanori Nagatsu, Yoshiaki Shikamura","doi":"10.1248/yakushi.24-00016","DOIUrl":"10.1248/yakushi.24-00016","url":null,"abstract":"In Japan, the Pharmaceutical and Medical Device Act was amended in December 2019, and now requires pharmacists to follow-up on patients during treatment. Although there have been some studies on the effectiveness of follow-ups by pharmacists, there are no reports on the status of implementation in clinical practice. We conducted a nationwide survey on follow-up care to investigate the actual situation. We randomly selected 10% of community pharmacies in each prefecture and conducted a survey. We built a web-based system for the collection of basic information on the pharmacies and follow-up cases. A total of 561 pharmacies were pre-entered. Of these, 110 pharmacies (19.6%) reported 326 follow-up cases. Information was provided to doctors in 129 cases (39.6%), of which prescription proposals were made in 10 (7.8%) instances. The follow-up implementation rate based on the number of prescriptions dispensed was estimated to be 0.84% (95% confidence interval: 0.76-0.94%). This study revealed the status of follow-ups in clinical practice. Pharmacists can contribute to the optimization of drug treatment by providing follow-up information to doctors and making prescription proposals.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"144 8","pages":"805-813"},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Chasing New Cancer Treatments: Current Status and Future Development of Boron Neutron Capture Therapy]. [追逐癌症新疗法：硼中子俘获疗法的现状与未来发展]。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 DOI: 10.1248/yakushi.24-00072

Makoto Shirakawa

{"title":"[Chasing New Cancer Treatments: Current Status and Future Development of Boron Neutron Capture Therapy].","authors":"Makoto Shirakawa","doi":"10.1248/yakushi.24-00072","DOIUrl":"https://doi.org/10.1248/yakushi.24-00072","url":null,"abstract":"Boron neutron capture therapy (BNCT) is expected to be a promising next-generation cancer treatment. In 2020, Japan, which has led the research on this treatment modality, was the first country in the world to approve BNCT. The boron agents that have been clinically applied in BNCT include a caged boron compound (mercaptoundecahydrododecaborate: BSH) and a boron-containing amino acid (p-boronophenylalanine: BPA). In particular, the BPA preparation Steboronine® is the only approved drug for BNCT. However, the problem with BPA is that it is poorly retained in the tumor and has very low solubility in water. This cannot be overlooked for BNCT, which requires large amounts of boron in the tumor. The high dosage volume, together with low tumor retention, leads to reduced therapeutic efficacy and increased physical burden on the patient. In the case of BSH, its insufficient penetration into the tumor is problematic. Based on drug delivery system (DDS) technology, we have developed a next-generation boron pharmaceutical superior to Steboronine®. Our approach involves the redevelopment of BPA using innovative ionic liquid formulation technology. Here, we describe previous boron agents and introduce our recent efforts in the development of boron compounds.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"144 9","pages":"871-876"},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Evaluation of the Stability and Antibacterial Activity of Burow's and Neo-Burow's Solutions was Prepared Using Different Methods]. [用不同方法制备的布罗氏溶液和新布罗氏溶液的稳定性和抗菌活性评估]。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 DOI: 10.1248/yakushi.24-00082

Masako Kinoshita, Rina Yamagishi, Yohei Iizaka, Masaki Takigawa, Yojiro Anzai, Atsushi Urano, Kaoru Hirose, Takehisa Hanawa, Hiroyuki Tanaka

{"title":"[Evaluation of the Stability and Antibacterial Activity of Burow's and Neo-Burow's Solutions was Prepared Using Different Methods].","authors":"Masako Kinoshita, Rina Yamagishi, Yohei Iizaka, Masaki Takigawa, Yojiro Anzai, Atsushi Urano, Kaoru Hirose, Takehisa Hanawa, Hiroyuki Tanaka","doi":"10.1248/yakushi.24-00082","DOIUrl":"https://doi.org/10.1248/yakushi.24-00082","url":null,"abstract":"Burow's solution is a 13% aluminum acetate solution used for treating chronic suppurative otitis media. However, multiple formulations for Burow's and neo-Burow's solutions are used as in-hospital preparations. Each formulation uses different types and amounts of reagents, and takes a different time to prepare. Thus, the ions, including aluminum ion (Al3+), and other molecules in the prepared Burow's and neo-Burow's solutions are not identical, and the pH also differs. Furthermore, details about the antibacterial activity of these preparations are unknown. This study evaluated the stability and antibacterial activity of four Burow's and two neo-Burow's solutions prepared using different methods. Preparation times ranged from 20 min to 3 d, and the pH ranged from 2.2 to 4, meaning some solutions were more acidic or more basic than the pH 3 devised by Burow. In addition, the Al3+ concentrations ranged from 0.05 to 1.51 mol/L, meaning some solutions were more concentrated or diluted than 13% aluminum acetate (0.64 mol/L). One of the Burow's solutions we prepared produced a white residue after 14 d, making it difficult to ensure stability. In addition, confirming the antibacterial activity of another Burow's solution against the test bacteria was problematic. Despite the differences in pH and Al3+ concentrations between the various Burow's and neo-Burow's solutions, the antibacterial activity was equivalent. It was considered necessary to use the basic data obtained in this study to select a formulation for each hospital. Evaluation of the antibacterial activity of each formulation in clinical settings will be a subject for future study.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"144 9","pages":"887-896"},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Progressing Basic Immunology for Development of New Therapeutic Medicines]. [发展基础免疫学，开发治疗新药]。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00154-F

Jun-Ichi Kashiwakura, Keigo Nishida

引用次数: 0

[Evaluation of Pharmacists' Active Intervention to Reduce Potentially Inappropriate Medications in Special Older Adult Nursing Home]. [评估药剂师积极干预以减少特殊老年护理院潜在的不适当药物]。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 Epub Date: 2023-10-31 DOI: 10.1248/yakushi.23-00090

Akiko Miki, Hiroki Satoh, Yusaku Matsumoto, Satoko Hori, Yasufumi Sawada

{"title":"[Evaluation of Pharmacists' Active Intervention to Reduce Potentially Inappropriate Medications in Special Older Adult Nursing Home].","authors":"Akiko Miki, Hiroki Satoh, Yusaku Matsumoto, Satoko Hori, Yasufumi Sawada","doi":"10.1248/yakushi.23-00090","DOIUrl":"10.1248/yakushi.23-00090","url":null,"abstract":"Currently, elderly care facilities that do not offer long-term care are not required to employ pharmacists, and duties such as the dispensing and distribution of medicines are entrusted to external pharmacies. Pharmacists seldom spend sufficient time at the facilities for elderly people requiring special care. Thus, in many cases, the pharmacists have insufficient knowledge of the residents' medication status, leading to their inability in determining whether the residents are receiving a suitable drug therapy. We previously documented various problems in the practices adopted by nursing staff (with negligible intervention by pharmacists) for assisting residents in taking their medications. In the present pilot study, we attempted to eliminate the use of potentially inappropriate medications by stationing a pharmacist at a nursing home for 24 h every week (3 d/week). We proactively collected information from nurses and other nursing staff and observed the residents' actual living conditions and medication use. As a result of this intervention, 56 prescriptions were changed. However, only two of these were changed exclusively based on the prescription information. Most prescriptions were able to change based on the information obtained by the pharmacist present at the facility. Therefore, pharmacists' presence at the facility (at least for a few hours) is necessary, as they can actively intervene and collaborate with other staff to prevent the use of potentially inappropriate medications.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":" ","pages":"137-142"},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71427423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Evaluation of Contractile Function Using Human iPS Cell-derived Cardiomyocytes]. [使用源自人类 iPS 细胞的心肌细胞评估收缩功能]。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00164-1

Junko Kurokawa, Satoshi Shimizu, Kazuho Sakamoto

{"title":"[Evaluation of Contractile Function Using Human iPS Cell-derived Cardiomyocytes].","authors":"Junko Kurokawa, Satoshi Shimizu, Kazuho Sakamoto","doi":"10.1248/yakushi.23-00164-1","DOIUrl":"10.1248/yakushi.23-00164-1","url":null,"abstract":"Cardiotoxicity induced by anti-cancer drugs is a significant concern for patients undergoing cancer treatment. Some anti-cancer drugs can damage cardiac muscle cells directly or indirectly, potentially leading to severe heart failure. Various risk factors, including the type and dosage of chemotherapy agents as well as patient background, contribute to the development of cardiotoxicity. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), which enable patient-specific toxicity prediction, hold great promise in this regard. However, the practical implementation of hiPSC-CMs-based prediction of anti-cancer drug-induced cardiotoxicity still faces hurdles. One major challenge involves establishing and optimizing experimental systems for evaluating contractile dysfunction, the ultimate output of heart failure, using hiPSC-CMs. Such efforts are currently underway globally, focusing on tailoring functional evaluation systems to the characteristics of hiPSC-CMs. In this paper, we provide an overview of the contraction mechanisms of cardiac cells and introduce a method of measuring contraction that we have developed, and discuss the current status of contractile function evaluation methods using hiPSC-CMs.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"144 3","pages":"251-255"},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140022694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Route to the Adoption of Quantitative NMR in the Japanese Pharmacopoeia]. [日本药典采用定量核磁共振的途径]。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00151-1

Yukihiro Goda

引用次数: 0

[Metabolic Activities Catalyzed by Human Cytochrome P450 (CYP) 2D6 and CYP3A Subfamily Members and Effect of Various Compounds, Including Endogenous Steroid Hormones, on These Activities]. [人类细胞色素 P450 (CYP) 2D6 和 CYP3A 亚家族成员催化的代谢活性以及各种化合物（包括内源性类固醇激素）对这些活性的影响]。

IF 0.3 4区医学

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan Pub Date : 2024-01-01 DOI: 10.1248/yakushi.23-00174

Toshiro Niwa

{"title":"[Metabolic Activities Catalyzed by Human Cytochrome P450 (CYP) 2D6 and CYP3A Subfamily Members and Effect of Various Compounds, Including Endogenous Steroid Hormones, on These Activities].","authors":"Toshiro Niwa","doi":"10.1248/yakushi.23-00174","DOIUrl":"10.1248/yakushi.23-00174","url":null,"abstract":"My research focused on the effects of various drugs on (1) dopamine formation from p-tyramine catalyzed by polymorphic cytochrome P450 (CYP or P450) 2D6 variants and (2) endogenous steroid hormone hydroxylation catalyzed by CYP3A subfamily members (CYP3A4, CYP3A5, CYP3A7). The activation (cooperativity) of metabolic reactions catalyzed by P450s was especially emphasized. The effects of various psychotropic agents on dopamine formation from p-tyramine, catalyzed by wild-type CYP2D6.1 and CYP2D6 variants, including CYP2D6.2 (Arg296Cys;Ser486Thr), CYP2D6.10 (Pro34Ser;Ser486Thr), and CYP2D6.39 (Ser486Thr) were compared. Michaelis (Km) and inhibition (Ki) constants of the psychotropic agents in the presence of CYP2D6.10 were higher than those observed in the presence of other CYP2D6 variants. Fluvoxamine, fluoxetine, milnacipran, and haloperidol activated CYP2D6-catalyzed dopamine formation [decreasing the Km and/or increasing the maximal velocity (kcat)], and this activation was CYP2D6 variant-dependent. Regarding the CYP3A subfamily, the effects of various compounds including endogenous steroid hormones on the 6β-hydroxylation of steroid hormones, such as testosterone, progesterone, and cortisol, were determined; it was found that testosterone, dehydroepiandrosterone, and/or α-naphthoflavone activated 6β-hydroxylation of cortisol and/or progesterone, but the effects varied in the presence of different CYP3A subfamily members. Further studies are required to confirm the mechanisms and therapeutic relevance of these activation phenomena.","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"144 2","pages":"197-202"},"PeriodicalIF":0.3,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139698431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0